LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 13

Search options

  1. Article ; Online: S3 Guideline Atopic dermatitis: Part 1 - General aspects, topical and non-drug therapies, special patient groups.

    Werfel, Thomas / Heratizadeh, Annice / Aberer, Werner / Augustin, Matthias / Biedermann, Tilo / Bauer, Andrea / Fölster-Holst, Regina / Kahle, Julia / Kinberger, Maria / Nemat, Katja / Neustädter, Irena / Peters, Eva / von Kiedrowski, Ralph / Schmid-Grendelmeier, Peter / Schmitt, Jochen / Schwennesen, Thomas / Simon, Dagmar / Spindler, Thomas / Traidl-Hoffmann, Claudia /
    Werner, Ricardo Niklas / Wollenberg, Andreas / Worm, Margitta / Ott, Hagen

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2024  Volume 22, Issue 1, Page(s) 137–153

    Abstract: This S3 guideline was created based on the European S3 guideline, with special consideration of the medical conditions in the German-speaking region and incorporating additions from the previous German-language version. The interdisciplinary guideline ... ...

    Abstract This S3 guideline was created based on the European S3 guideline, with special consideration of the medical conditions in the German-speaking region and incorporating additions from the previous German-language version. The interdisciplinary guideline commission consisted of representatives from the German Dermatological Society, the Professional Association of German Dermatologists, the Austrian Society of Dermatology and Venereology, the Swiss Society of Dermatology and Venereology, the German Society for Allergology and Clinical Immunology, the German Society for Pediatric and Adolescent Medicine, the Professional Association of Pediatricians and Adolescent Medicine, the Society for Pediatric Allergology and Environmental Medicine, the German Society for Pediatric Rehabilitation and Prevention, the German Society for Psychosomatic Medicine and Medical Psychotherapy, the German Network for Health Services Research, the German Eczema Association and the German Allergy and Asthma Association. This first part of the guideline focuses on the definition and diagnostic aspects of atopic dermatitis (AD), addressing topical therapy as well as non-pharmacological treatment approaches such as UV therapy, psychoeducational therapy, dietary interventions for AD, allergen immunotherapy for AD, and complementary medicine. This part of the guideline also covers specific aspects of AD in children and adolescents, during pregnancy and lactation, and in the context of family planning. Additionally, it addresses occupational aspects of AD and highlights the perspective of the patients. The second part of the guideline, published separately, addresses the systemic therapy of AD.
    MeSH term(s) Adolescent ; Female ; Pregnancy ; Humans ; Child ; Dermatitis, Atopic/therapy ; Dermatitis, Atopic/drug therapy ; Asthma
    Language English
    Publishing date 2024-01-03
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.15230
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: S3-Leitlinie Atopische Dermatitis: Teil 2 - Systemische Therapie: S3 guideline Atopic dermatitis: Part 2 - Systemic treatment.

    Werfel, Thomas / Heratizadeh, Annice / Aberer, Werner / Augustin, Matthias / Biedermann, Tilo / Bauer, Andrea / Fölster-Holst, Regina / Kahle, Julia / Kinberger, Maria / Nemat, Katja / Neustädter, Irena / Peters, Eva / von Kiedrowski, Ralph / Schmid-Grendelmeier, Peter / Schmitt, Jochen / Schwennesen, Thomas / Simon, Dagmar / Spindler, Thomas / Traidl-Hoffmann, Claudia /
    Werner, Ricardo Niklas / Wollenberg, Andreas / Worm, Margitta / Ott, Hagen

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2024  Volume 22, Issue 2, Page(s) 307–322

    MeSH term(s) Humans ; Dermatitis, Atopic/diagnosis ; Dermatitis, Atopic/drug therapy ; Administration, Cutaneous
    Language English
    Publishing date 2024-02-15
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.15229_g
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Patients' and Caregivers' Experiences With Atopic Dermatitis-Related Burden, Medical Care, and Treatments in 8 Countries.

    Capozza, Korey / Funk, Melanie / Hering, Marjolaine / Lang, Jessica / Merhand, Stephanie / Manion, Rachael / Orevillo, Kara / Picozza, Mario / Proctor, Andrew / Schwennesen, Thomas / Begolka, Wendy Smith / Tullos, Kathryn / Talent, Cheryl / Tu, Michelle / Vastrup, Anne Skov / Schwartz, Alan

    The journal of allergy and clinical immunology. In practice

    2022  Volume 11, Issue 1, Page(s) 264–273.e1

    Abstract: Background: Previous studies have documented the high patient and caregiver burden associated with atopic dermatitis (AD). Less is known about the factors-especially those related to treatment options and the delivery of medical care-that may relate to ... ...

    Abstract Background: Previous studies have documented the high patient and caregiver burden associated with atopic dermatitis (AD). Less is known about the factors-especially those related to treatment options and the delivery of medical care-that may relate to burden and unmet needs among patients and their caregivers.
    Objective: Our primary aim was to characterize and compare health-related quality of life, long-term control of symptoms, satisfaction with treatments, the financial burden, and the prevalence of patient-centered care among adult and pediatric patients with AD in 8 developed nations.
    Methods: We developed a 53-item anonymous online survey for adult patients and caregivers of children with AD (N = 3171; self-reported disease severity: 8.2% clear, 33.2% mild, 41.1% moderate, 17.6% severe). The survey included questions across 7 domains selected by a steering committee of 11 patient organizations that advocate for patients with AD in the 8 countries. We used validated instruments when available including the 5-level EuroQol five-dimensional questionnaire and the Atopic Dermatitis Control Tool. The survey was offered in 5 languages and promoted through social media and other communication channels of the patient organizations.
    Results: The health-related quality-of-life scores for adult patients with AD (driven by 2 domains: pain/discomfort and anxiety/depression) were worse than those reported for asthma and type 2 diabetes in previous studies (0.72; 95% CI, 0.65-0.78). Patients and caregivers reported substantial financial impacts even in countries with government-funded health care systems, though the greatest impact was in the United States. In all countries, adults reported better control of symptoms than children, but neither group nor any nationality reported adequate control on average (rescaled mean, 57.5; 95% CI, 56.1-58.9), and control correlated negatively with disease severity. Similarly, satisfaction with treatments, which was moderate across countries on average, was much lower for respondents with more severe disease symptoms (F(3,3165) = 5.5; P < .001). Patients who saw a specialist (a dermatologist or an allergist) instead of a general practitioner for AD care indicated better long-term control of symptoms (by 4 points on average on the 100-point scale; 95% CI, 2.6-5.4; P < .001). Finally, self-management training and shared decision making were uncommonly reported by patients in all countries except by respondents from the United States, but both were associated with better long-term control of symptoms and higher satisfaction.
    Conclusions: The burden of AD, evaluated as health-related quality-of-life detriments, financial impacts, and uncontrolled symptoms, is significant and highest for patients with more severe atopic dermatitis who report greater challenges in achieving symptom resolution with existing treatments and approaches to care. The better outcomes associated with respondents who saw specialists suggest that patients, especially those with more severe AD, might benefit from medical care that is guided by providers with more in-depth knowledge of this complex condition. Finally, wider use of patient-centered care practices (specifically, self-management training and shared decision making) could improve outcomes and boost satisfaction with treatments for AD, though more research on this topic is warranted.
    MeSH term(s) Adult ; Humans ; Child ; Dermatitis, Atopic/epidemiology ; Dermatitis, Atopic/therapy ; Dermatitis, Atopic/diagnosis ; Quality of Life ; Caregivers ; Diabetes Mellitus, Type 2 ; Patient Care ; Severity of Illness Index
    Language English
    Publishing date 2022-11-02
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2843237-X
    ISSN 2213-2201 ; 2213-2198
    ISSN (online) 2213-2201
    ISSN 2213-2198
    DOI 10.1016/j.jaip.2022.10.032
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Article ; Online: S2k-Leitlinie: Rosazea.

    Clanner-Engelshofen, Benjamin M / Bernhard, Dominik / Dargatz, Sonja / Flaig, Michael J / Gieler, Uwe / Kinberger, Maria / Klövekorn, Winfried / Kuna, Anne-Charlotte / Läuchli, Severin / Lehmann, Percy / Nast, Alexander / Pleyer, Uwe / Schaller, Martin / Schöfer, Helmut / Steinhoff, Martin / Schwennesen, Thomas / Werner, Ricardo Niklas / Zierhut, Manfred / Reinholz, Markus

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2022  Volume 20, Issue 8, Page(s) 1147–1167

    Language English
    Publishing date 2022-08-21
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.14849_g
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  5. Article ; Online: S2k guideline: Rosacea.

    Clanner-Engelshofen, Benjamin M / Bernhard, Dominik / Dargatz, Sonja / Flaig, Michael J / Gieler, Uwe / Kinberger, Maria / Klövekorn, Winfried / Kuna, Anne-Charlotte / Läuchli, Severin / Lehmann, Percy / Nast, Alexander / Pleyer, Uwe / Schaller, Martin / Schöfer, Helmut / Steinhoff, Martin / Schwennesen, Thomas / Werner, Ricardo Niklas / Zierhut, Manfred / Reinholz, Markus

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2022  Volume 20, Issue 8, Page(s) 1147–1165

    Abstract: This updated and upgraded S2k guideline deals with the diagnosis and treatment of rosacea, which is a common, chronic inflammatory skin disease mostly affecting the face. Initially, rosacea is characterized by recurrent erythema, telangiectasia and ... ...

    Abstract This updated and upgraded S2k guideline deals with the diagnosis and treatment of rosacea, which is a common, chronic inflammatory skin disease mostly affecting the face. Initially, rosacea is characterized by recurrent erythema, telangiectasia and flushing. Later, the inflammatory component predominates, with persistent erythema with follicular papules, papulopustules and pustules. The development of phyma, which usually occurs on the acral localizations, is the most severe manifestation. For the treatment of rosacea, the interdisciplinary guideline committee, with representatives of the German Dermatological Society (DDG), the Professional Association of German Dermatologists (BVDD), the German Opthalmological Society (DOG), the Society for Dermopharmacy (GD), the Swiss Society for Dermatology and Venereology (SGDV) and the German Rosacea Aid e. V., recommends the avoidance of trigger factors and topical applications of metronidazole, azelaic acid or ivermectin. For symptomatic treatment of persistent centrofacial erythema, the topical vasoconstrictors brimonidine or oxymetazoline can also be used. Systemic therapy is recommended for therapy-resistant and severe forms of rosacea papulopustulosa. The drug of choice is low-dose doxycycline. Alternatively, low-dose isotretinoin can be recommended. Ocular rosacea should be treated with lid margin hygiene. For topical treatment, ciclosporin eye drops, azithromycin, ivermectin or metronidazole are suggested.
    MeSH term(s) Brimonidine Tartrate ; Dermatologic Agents/therapeutic use ; Erythema/drug therapy ; Humans ; Ivermectin/therapeutic use ; Metronidazole/therapeutic use ; Rosacea/diagnosis ; Rosacea/drug therapy
    Chemical Substances Dermatologic Agents ; Metronidazole (140QMO216E) ; Brimonidine Tartrate (4S9CL2DY2H) ; Ivermectin (70288-86-7)
    Language English
    Publishing date 2022-08-05
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.14849
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: S3 guideline Atopic dermatitis: Part 2 - Systemic treatment.

    Werfel, Thomas / Heratizadeh, Annice / Aberer, Werner / Augustin, Matthias / Biedermann, Tilo / Bauer, Andrea / Fölster-Holst, Regina / Kahle, Julia / Kinberger, Maria / Nemat, Katja / Neustädter, Irena / Peters, Eva / von Kiedrowski, Ralph / Schmid-Grendelmeier, Peter / Schmitt, Jochen / Schwennesen, Thomas / Simon, Dagmar / Spindler, Thomas / Traidl-Hoffmann, Claudia /
    Werner, Ricardo Niklas / Wollenberg, Andreas / Worm, Margitta / Ott, Hagen

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2023  Volume 22, Issue 2, Page(s) 307–320

    Abstract: The present S3 guideline was created based on the European English-language S3 guideline, with special consideration given to the medical conditions in the German-speaking region, and with additions from the previous German-language version, in ... ...

    Abstract The present S3 guideline was created based on the European English-language S3 guideline, with special consideration given to the medical conditions in the German-speaking region, and with additions from the previous German-language version, in accordance with the criteria of the AWMF. This second part of the guideline addresses the systemic therapy of atopic dermatitis (AD). It covers topics such as the indication for systemic therapy in children, adolescents, and adult patients with AD. Furthermore, it addresses all medications approved for AD, such as the biologics dupilumab and tralokinumab, the Janus kinase inhibitors abrocitinib, baricitinib, and upadacitinib, as well as conventional immunosuppressive therapies with systemic glucocorticosteroids and ciclosporin. Additionally, it discusses systemic off-label therapies. The first part of the guideline, published separately, includes the definition and diagnostic aspects of AD, describes topical therapy, non-drug therapy approaches, and addresses aspects related to special patient groups.
    MeSH term(s) Adolescent ; Adult ; Child ; Humans ; Dermatitis, Atopic/diagnosis ; Dermatitis, Atopic/drug therapy ; Administration, Cutaneous ; Biological Products ; Cyclosporine ; Immunosuppression Therapy ; Treatment Outcome
    Chemical Substances Biological Products ; Cyclosporine (83HN0GTJ6D)
    Language English
    Publishing date 2023-12-31
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.15229
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Article ; Online: Update "Systemic treatment of atopic dermatitis" of the S2k-guideline on atopic dermatitis.

    Werfel, Thomas / Heratizadeh, Annice / Aberer, Werner / Ahrens, Frank / Augustin, Matthias / Biedermann, Tilo / Diepgen, Thomas / Fölster-Holst, Regina / Kahle, Julia / Kapp, Alexander / Nemat, Katja / Peters, Eva / Schlaeger, Martin / Schmid-Grendelmeier, Peter / Schmitt, Jochen / Schwennesen, Thomas / Staab, Doris / Traidl-Hoffmann, Claudia / Werner, Ricardo /
    Wollenberg, Andreas / Worm, Margitta / Ott, Hagen

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2021  Volume 19, Issue 1, Page(s) 151–168

    Abstract: This guideline is an update from August 2020 the S2k-guideline "Atopic dermatitis" published in 2015. The reason for updating this chapter of the guideline were the current developments in the field of systemic therapy of atopic dermatitis. The agreed ... ...

    Abstract This guideline is an update from August 2020 the S2k-guideline "Atopic dermatitis" published in 2015. The reason for updating this chapter of the guideline were the current developments in the field of systemic therapy of atopic dermatitis. The agreed recommendations for systemic treatment in atopic dermatitis of the present guideline are based on current scientific data. Due to the approval of dupilumab for the treatment of moderate to severe atopic dermatitis, which cannot be treated sufficiently with topical drugs alone, this part of the guideline has now been adapted and newly consented. The indication for systemic therapy and the therapeutic response to topical and systemic treatment should be recorded and documented in a suitable form in clinic and practice. A standardized documentation of the indication for system therapy in atopic dermatitis can be recommended and is also part of the updated chapter of this guideline.
    MeSH term(s) Administration, Cutaneous ; Antibodies, Monoclonal/therapeutic use ; Dermatitis, Atopic/drug therapy ; Eczema ; Humans
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2021-01-22
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.14371
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  8. Article ; Online: [No title information]

    Werfel, Thomas / Heratizadeh, Annice / Aberer, Werner / Ahrens, Frank / Augustin, Matthias / Biedermann, Tilo / Diepgen, Thomas / Fölster-Holst, Regina / Kahle, Julia / Kapp, Alexander / Nemat, Katja / Peters, Eva / Schlaeger, Martin / Schmid-Grendelmeier, Peter / Schmitt, Jochen / Schwennesen, Thomas / Staab, Doris / Traidl-Hoffmann, Claudia / Werner, Ricardo /
    Wollenberg, Andreas / Worm, Margitta / Ott, Hagen

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2021  Volume 19, Issue 1, Page(s) 151–169

    Title translation Aktualisierung„ Systemtherapie bei Neurodermitis“ zur S2k-Leitlinie Neurodermitis.
    Language German
    Publishing date 2021-01-25
    Publishing country Germany
    Document type Journal Article
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/ddg.14371_g
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  9. Article ; Online: Safety and efficacy of pimecrolimus cream 1% in the daily practice: results of a patient self-observation study in patients with atopic dermatitis.

    Luger, Thomas A / Gollnick, Harald / Schwennesen, Thomas / Bextermöller, Raphael / Freytag, Siegfried / Bräutigam, Matthias

    Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG

    2007  Volume 5, Issue 10, Page(s) 908–914

    Abstract: Background: Pimecrolimus cream 1% has proven to be well-tolerated and effective in controlled clinical studies in patients with atopic dermatitis (AD). In a 15-week patient self-observation study, safety and efficacy was investigated in the daily ... ...

    Abstract Background: Pimecrolimus cream 1% has proven to be well-tolerated and effective in controlled clinical studies in patients with atopic dermatitis (AD). In a 15-week patient self-observation study, safety and efficacy was investigated in the daily practice.
    Patients and methods: 3502 patients with AD (mean age 26.2 +/- 18 years, 62% female) received pimecrolimus cream 1% from 810 physicians in the German Federal Republic. The severity of the disease was assessed at baseline, two times during the 15-week observation period and at the end of treatment. Patients recorded daily the degree of erythema and pruritus. At the end of treatment, safety and efficacy were assessed by the physician based on patient's daily records and by the patient.
    Results: The percentage of patients with severe or massive AD decreased from 25% to 7%, whereas the percentage of patients without or with mild symptoms increased from 9% to 55%.The efficacy of treatment was rated by physicians as good or very good in 83.5% of cases and by 79% of patients. At baseline 35% of the patients were free of flares as compared to 75% at the end of therapy. Disease control was better in patients who followed the recommended treatment algorithm for pimecrolimus cream. Tolerability was mostly rated as good or very good.
    Conclusion: Treatment with pimecrolimus cream 1% for patients with AD is well-tolerated and effective in daily practice.
    MeSH term(s) Adult ; Dermatitis, Atopic/diagnosis ; Dermatitis, Atopic/drug therapy ; Dermatitis, Atopic/epidemiology ; Dermatologic Agents/administration & dosage ; Dermatologic Agents/adverse effects ; Drug Administration Schedule ; Female ; Germany/epidemiology ; Humans ; Male ; Self-Examination/statistics & numerical data ; Tacrolimus/administration & dosage ; Tacrolimus/adverse effects ; Tacrolimus/analogs & derivatives ; Treatment Outcome
    Chemical Substances Dermatologic Agents ; pimecrolimus (7KYV510875) ; Tacrolimus (WM0HAQ4WNM)
    Language German
    Publishing date 2007-10
    Publishing country Germany
    Document type Clinical Conference ; Journal Article ; Multicenter Study
    ZDB-ID 2093479-8
    ISSN 1610-0387 ; 1610-0379
    ISSN (online) 1610-0387
    ISSN 1610-0379
    DOI 10.1111/j.1610-0387.2007.06510.x
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: S2k guideline on diagnosis and treatment of atopic dermatitis - short version.

    Werfel, Thomas / Heratizadeh, Annice / Aberer, Werner / Ahrens, Frank / Augustin, Matthias / Biedermann, Tilo / Diepgen, Thomas / Fölster-Holst, Regina / Gieler, Uwe / Kahle, Julia / Kapp, Alexander / Nast, Alexander / Nemat, Katja / Ott, Hagen / Przybilla, Bernhard / Roecken, Martin / Schlaeger, Martin / Schmid-Grendelmeier, Peter / Schmitt, Jochen /
    Schwennesen, Thomas / Staab, Doris / Worm, Margitta

    Allergo journal international

    2016  Volume 25, Page(s) 82–95

    Abstract: Atopic dermatitis (AD) represents a pruritic, non-contagious, chronic or chronically relapsing, inflammatory skin disease. The course of the disease may be complicated by bacterial or viral superinfections. The first manifestation of the disease and ... ...

    Abstract Atopic dermatitis (AD) represents a pruritic, non-contagious, chronic or chronically relapsing, inflammatory skin disease. The course of the disease may be complicated by bacterial or viral superinfections. The first manifestation of the disease and further flare-ups are due to genetic predisposition and also to a variety of further trigger factors. The therapy regimen should be adapted to disease symptoms that are actually present and consider individual features of the disease as reported by the patients or their parents. This short version of the German guideline on AD provides an overview of evidence-based diagnostic and treatment options. All recommendations made here are the result of a consensus of the scientific medical societies, working groups and support groups based on scientific data published to date. Abstracts and details of the studies cited are provided in the long version of this guideline (see: www.awmf.org).
    Language English
    Publishing date 2016-05-02
    Publishing country Germany
    Document type Review ; Journal Article
    ISSN 2197-0378
    ISSN 2197-0378
    DOI 10.1007/s40629-016-0110-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top